Cat. No.: HY-104074

Pocapavir

(Synonyms: SCH-48973; V-073)

5 Cited Publications

Avis client

Based on 5 publication(s) in Google Scholar

Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.59%
CAS No.: 146949-21-5
Formule: C₂₁H₁₇Cl₃O₃
Masse moléculaire:423.72

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Pocapavir Chemical Structure

CAS No.: 146949-21-5

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
Chemical Information
Publications (5)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Cellular Effect

Cell Line	Type	Value	Description	References
H1-HeLa	CC₅₀	>100 μM Compound: 29	Cytotoxicity against human H1HeLa cells assessed as decrease in cell viability after 3 days by MTT assay Cytotoxicity against human H1HeLa cells assessed as decrease in cell viability after 3 days by MTT assay	[PMID: 28581749]
HeLa	CC₅₀	16 μM Compound: 29	Cytotoxicity aganist human HeLa cells assessed as decrease in cell viability after 2 days by MTT assay Cytotoxicity aganist human HeLa cells assessed as decrease in cell viability after 2 days by MTT assay	[PMID: 28581749]
HeLa	EC₅₀	0.08 μM Compound: 29	Antiviral activity against Human poliovirus 3 infected in human HeLa cells assessed as protection against virus induced cytopathic effect after 2 days by MTT assay Antiviral activity against Human poliovirus 3 infected in human HeLa cells assessed as protection against virus induced cytopathic effect after 2 days by MTT assay	[PMID: 28581749]
LLC-MK2	EC₅₀	0.003 μM Compound: V-073	Antiviral activity against Poliovirus P712 serotype PV2 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus P712 serotype PV2 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.007 μM Compound: V-073	Antiviral activity against Poliovirus Lansing serotype PV2 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus Lansing serotype PV2 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.008 μM Compound: V-073	Antiviral activity against Poliovirus 10693 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10693 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.008 μM Compound: V-073	Antiviral activity against Poliovirus 10695 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10695 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.009 μM Compound: V-073	Antiviral activity against Poliovirus 10234 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10234 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.01 μM Compound: V-073	Antiviral activity against Poliovirus 10220 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10220 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.01 μM Compound: V-073	Antiviral activity against Poliovirus 10223 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10223 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.011 μM Compound: V-073	Antiviral activity against Poliovirus 10237 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10237 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.014 μM Compound: V-073	Antiviral activity against Poliovirus 10238 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10238 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.014 μM Compound: V-073	Antiviral activity against Poliovirus 10239 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10239 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.014 μM Compound: V-073	Antiviral activity against Poliovirus 10694 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10694 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.015 μM Compound: V-073	Antiviral activity against Poliovirus 10222 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10222 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.015 μM Compound: V-073	Antiviral activity against Poliovirus 10240 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10240 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.016 μM Compound: V-073	Antiviral activity against Poliovirus PV2-P712 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus PV2-P712 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.017 μM Compound: V-073	Antiviral activity against Poliovirus 10225 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10225 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.017 μM Compound: V-073	Antiviral activity against Poliovirus 10242 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10242 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.017 μM Compound: V-073	Antiviral activity against Poliovirus PV1-LSc/2ab serotype PV1 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus PV1-LSc/2ab serotype PV1 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.018 μM Compound: V-073	Antiviral activity against Poliovirus 10235 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10235 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.018 μM Compound: V-073	Antiviral activity against Poliovirus 10691 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10691 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.018 μM Compound: V-073	Antiviral activity against Poliovirus Brunhilde serotype PV1 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus Brunhilde serotype PV1 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.019 μM Compound: V-073	Antiviral activity against Poliovirus 10226 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10226 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.019 μM Compound: V-073	Antiviral activity against Poliovirus 10227 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10227 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.019 μM Compound: V-073	Antiviral activity against Poliovirus 10232 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10232 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.02 μM Compound: V-073	Antiviral activity against Poliovirus 10229 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10229 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.02 μM Compound: V-073	Antiviral activity against Poliovirus PV3-Leon serotype PV3 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus PV3-Leon serotype PV3 vaccine-derived infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.021 μM Compound: V-073	Antiviral activity against Poliovirus 10668 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10668 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.023 μM Compound: V-073	Antiviral activity against Poliovirus 10219 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10219 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.024 μM Compound: V-073	Antiviral activity against Poliovirus 10233 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10233 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.026 μM Compound: V-073	Antiviral activity against Poliovirus MEF-1 serotype PV2 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus MEF-1 serotype PV2 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.027 μM Compound: V-073	Antiviral activity against Poliovirus 10221 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10221 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.028 μM Compound: V-073	Antiviral activity against Poliovirus 10231 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10231 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.029 μM Compound: V-073	Antiviral activity against Poliovirus 10236 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10236 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.029 μM Compound: V-073	Antiviral activity against Poliovirus 10690 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10690 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.029 μM Compound: V-073	Antiviral activity against Poliovirus 10692 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10692 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.029 μM Compound: V-073	Antiviral activity against Poliovirus 10805 serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10805 serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.036 μM Compound: V-073	Antiviral activity against Poliovirus 10230 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10230 serotype PV2 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.038 μM Compound: V-073	Antiviral activity against Poliovirus 10243 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10243 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.042 μM Compound: V-073	Antiviral activity against Poliovirus 10689 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10689 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.042 μM Compound: V-073	Antiviral activity against Poliovirus 10804 serotype PV3 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10804 serotype PV3 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.062 μM Compound: V-073	Antiviral activity against Poliovirus Saukett serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus Saukett serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.069 μM Compound: V-073	Antiviral activity against Poliovirus 10224 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10224 serotype PV1 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.076 μM Compound: V-073	Antiviral activity against Poliovirus Mahoney serotype PV1 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus Mahoney serotype PV1 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.083 μM Compound: V-073	Antiviral activity against Poliovirus 10241 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10241 serotype PV1 obtained from circulating vaccine infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.109 μM Compound: V-073	Antiviral activity against Poliovirus Leon serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus Leon serotype PV3 infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]
LLC-MK2	EC₅₀	0.126 μM Compound: V-073	Antiviral activity against Poliovirus 10228 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect Antiviral activity against Poliovirus 10228 serotype PV2 obtained from immunodeficient chronic excretor infected in pig LLC-MK2 cells assessed as inhibition of viral-replication induced cytopathic effect	[PMID: 19635956]

In Vitro

Pocapavir belongs to a picornavirus antiviral mechanistic class called capsid inhibitors that block virus uncoating and viral RNA release into cells, which in turn prevents virus replication^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 146949-21-5
Appearance Solid
Masse moléculaire 423.72
Formule C₂₁H₁₇Cl₃O₃
Color White to off-white
SMILES

ClC1=C(OCC2=CC=C(COC3=CC=C(OC)C=C3Cl)C=C2)C(Cl)=CC=C1
Synonyms

SCH-48973; V-073
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All

Sort by:

Journal Impact Factor

J Clin Immunol

Chronic Enteroviral Meningoencephalitis in a Patient with Good's Syndrome Treated with Pocapavir. [Abstract]

2022 Nov;42(8):1611-1613. PMID: 35870029
SSRN

2026 Mar 7.
bioRxiv

Single-cell virology: On-chip, quantitative characterization of the dynamics of virus spread from one single cell to another. [Abstract]

2024 Sep 26:2024.09.25.615011. PMID: 39386720
Research Square Preprint

2022 Feb.
bioRxiv

2020 Apr.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (236.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3600 mL

11.8002 mL

23.6005 mL

5 mM

0.4720 mL

2.3600 mL

4.7201 mL

10 mM

0.2360 mL

1.1800 mL

2.3600 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (271 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Collett MS, et al. Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model. J Infect Dis. 2017 Feb 1;215(3):335-343. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3600 mL	11.8002 mL	23.6005 mL	59.0012 mL
	5 mM	0.4720 mL	2.3600 mL	4.7201 mL	11.8002 mL
	10 mM	0.2360 mL	1.1800 mL	2.3600 mL	5.9001 mL
	15 mM	0.1573 mL	0.7867 mL	1.5734 mL	3.9334 mL
	20 mM	0.1180 mL	0.5900 mL	1.1800 mL	2.9501 mL
	25 mM	0.0944 mL	0.4720 mL	0.9440 mL	2.3600 mL
	30 mM	0.0787 mL	0.3933 mL	0.7867 mL	1.9667 mL
	40 mM	0.0590 mL	0.2950 mL	0.5900 mL	1.4750 mL
	50 mM	0.0472 mL	0.2360 mL	0.4720 mL	1.1800 mL
	60 mM	0.0393 mL	0.1967 mL	0.3933 mL	0.9834 mL
	80 mM	0.0295 mL	0.1475 mL	0.2950 mL	0.7375 mL
	100 mM	0.0236 mL	0.1180 mL	0.2360 mL	0.5900 mL

Keywords

Pocapavir

5 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Pocapavir

Anti-Infection Compound Library

Antiviral Compound Library

Orally Active Compound Library

Targeted Diversity Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Pocapavir

Activité biologique

Chemical Information

Publications (5)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Pocapavir

Anti-Infection Compound Library

Antiviral Compound Library

Orally Active Compound Library

Targeted Diversity Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Pocapavir

Activité biologique

Chemical Information

Publications (5)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Pocapavir Related Classifications

HY-104074 Related Classifications